Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04634578 · ClinicalTrials.gov registry record · Phase 2
Bevacizumab Treatment For Type 1 ROP
A Phase 2 study of Retinopathy of Prematurity, sponsored by Jaeb Center for Health Research.
- Active
- Registry status
- Phase 2
- Development phase
- 77
- Enrollment target
- 20
- Study locations
NCT04634578 is a Phase 2 study of Retinopathy of Prematurity that is active but no longer recruiting, run by Jaeb Center for Health Research. The registered enrollment target is 77 participants, below the 358-participant average among 7 other Retinopathy of Prematurity trials with a reported enrollment target (78% lower). The trial reports 20 study locations across 13 states.
The verdict
NCT04634578, a Phase 2 study of Retinopathy of Prematurity, is active but no longer recruiting, sponsored by Jaeb Center for Health Research.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 77 participants
- Enrollment target
- 20
- Study locations
Study Summary
Type 1 retinopathy of prematurity in zone I represents the most severe type of ROP and has the worst prognosis. It is unknown whether low-dose bevacizumab will be successful in these severe cases. Also unknown is the timing and extent of peripheral retinal vascularization after low-dose bevacizumab compared with the standard dose. The current study will evaluate whether doses of 0.063 mg and 0.25mg are effective as treatment for type 1 ROP, with ROP and retinal vessels all in zone I.
Conditions Studied
Interventions
- DRUG Bevacizumab
Study Locations (20)
California
- Univ of California, Irvine- Gavin Herbert Eye Institute - Irvine
- Jules Stein Eye Institute at the University of California, Los Angeles - Los Angeles
- University of California, Davis - Sacramento
- University of California San Francisco Department of Ophthalmology - San Francisco
Illinois
- Ann & Robert H. Lurie Children's Hospital of Chicago - Chicago
- U of Illinois at Chicago Eye and Ear Infirmary - Chicago
- University of Chicago - Hyde Park
Indiana
- Indiana University School of Medicine - Indianapolis
- Riley Hospital for Children - Indianapolis
Ohio
- Cincinnati Children's Hospital - Cincinnati
- Pediatric Ophthalmology Associates, Inc. - Columbus
Arkansas
- Arkansas Childrens Hospital/ University of Arkansas Medical Sciences - Little Rock
Georgia
- The Emory Eye Center - Atlanta
Kentucky
- UK Ophthalmology and Visual Sciences, The Eye Clinic - Lexington
Maryland
- Greater Baltimore Medical Center - Baltimore
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 77 participants |
| Start Date | 2022-05-01 |
| Est. Completion | 2027-07-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04634578
The ClinicalTrials.gov registry entry for NCT04634578 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 77 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 358-participant average among 7 other Retinopathy of Prematurity trials with a reported enrollment target (78% lower). The listed sponsor is Jaeb Center for Health Research, which has 119 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Retinopathy of Prematurity appearing as the primary indexed condition, and to 1 intervention - of which Bevacizumab is the first listed.
NCT04634578 reports 20 study locations spanning 13 distinct geographic areas - top geographies include California, Illinois, Indiana.
Frequently Asked Questions
What is clinical trial NCT04634578 about?
NCT04634578 is a clinical study titled "Bevacizumab Treatment For Type 1 ROP". Type 1 retinopathy of prematurity in zone I represents the most severe type of ROP and has the worst prognosis. It is unknown whether low-dose bevacizumab will be successful in these severe cases. Also unknown is the timing and extent of peripheral retinal vascularization after low-dose bevacizumab ...
What is the current status of trial NCT04634578?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 77 participants. The study started on 2022-05-01. Estimated completion is 2027-07-01.
What conditions does trial NCT04634578 study?
This clinical trial studies the following conditions: Retinopathy of Prematurity.
What interventions are being tested in trial NCT04634578?
The interventions under investigation include: Bevacizumab (DRUG).
Who is sponsoring clinical trial NCT04634578?
This trial is sponsored by Jaeb Center for Health Research, which has 119 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04634578 being conducted?
This trial has 20 study locations across Arkansas, California, Georgia, Illinois, Indiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Retinopathy of Prematurity
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Imaging Retinal Vasculature in Infant Eyes
RECRUITING
-
Clinical and Genetic Analysis of ROP
RECRUITING
-
Retinal Microanatomy in Retinopathy of Prematurity (BabySTEPS2)
RECRUITING · NA
-
Validation of i-ROP DL to Detect More Than Mild ROP
ACTIVE NOT RECRUITING · NA
-
Extension Study to Evaluate the Long-Term Outcomes of Pediatric Patients Who Received Treatment for Retinopathy of Prematurity in the VGFTe-ROP-1920 Study (Acronym: Butterfleye Next)
ACTIVE NOT RECRUITING
-
The Effects of Light Reduction on Retinopathy of Prematurity (Light-ROP)
COMPLETED · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.